Skip to content
Vpriv(velaglucerase alfa)
Vpriv (velaglucerase alfa) is an enzyme pharmaceutical. Velaglucerase alfa was first approved as Vpriv on 2010-02-26. It is used to treat gaucher disease in the USA. It has been approved in Europe to treat gaucher disease.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Vpriv
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Velaglucerase alfa
Tradename
Proper name
Company
Number
Date
Products
VPRIVvelaglucerase alfaTakedaN-22575 RX2010-02-26
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
vprivBiologic Licensing Application2020-12-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
gaucher diseaseOrphanet_355D005776E75.22
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AB: Enzymes for alimentary tract and metabolism
— A16AB10: Velaglucerase alfa
HCPCS
Code
Description
J3385
Injection, velaglucerase alfa, 100 units
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gaucher diseaseD005776Orphanet_355E75.222373113
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVELAGLUCERASE ALFA
INNvelaglucerase alfa
Description
Velaglucerase alfa, sold under the brand name Vpriv and manufactured by Shire plc, is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1. It has an identical amino acid sequence to the naturally occurring enzyme. It was approved for use by the U.S. Food and Drug Administration (FDA) on February 26, 2010.
Classification
Enzyme
Drug classenzymes
Image (chem structure or protein)VELAGLUCERASE ALFA
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB2WKL
CAS-ID884604-91-5
RxCUI901805
ChEMBL IDCHEMBL1201865
ChEBI ID—
PubChem CID—
DrugBankDB06720
UNII ID23HYE36B0I (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vpriv - Takeda
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Vpriv - Shire
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 321 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
32,385 adverse events reported
View more details